| 000 | 00853 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250518044902.0 | ||
| 264 | 0 | _c20190712 | |
| 008 | 201907s 0 0 eng d | ||
| 022 | _a1474-547X | ||
| 024 | 7 |
_a10.1016/S0140-6736(19)30694-4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGray, William A | |
| 245 | 0 | 0 |
_aKey points to consider in the IMPERIAL trial - Author's reply. _h[electronic resource] |
| 260 |
_bLancet (London, England) _c06 2019 |
||
| 300 |
_a2490 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 | _aDrug-Eluting Stents |
| 650 | 0 | 4 | _aFemoral Artery |
| 650 | 0 | 4 | _aPaclitaxel |
| 650 | 0 | 4 | _aPolymers |
| 650 | 0 | 4 | _aStents |
| 773 | 0 |
_tLancet (London, England) _gvol. 393 _gno. 10190 _gp. 2490 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0140-6736(19)30694-4 _zAvailable from publisher's website |
| 999 |
_c29829188 _d29829188 |
||